Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance

Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Transl Lung Cancer Res
Main Authors: Minari, Roberta, Bordi, Paola, Tiseo, Marcello
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2016
Assuntos:
Review Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5233880/
https://ncbi.nlm.nih.gov/pubmed/28149764
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/tlcr.2016.12.02
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados